FULL VET CRO

OCR, your partner for comparative medicine studies

OCR is specialized in the design of clinical studies of pets with naturally occurring pathologies
for efficacy assessment of drug candidates and medical devices for Human Health.

OCR gets a makeover


OCR is moving its premises to the IRCL (Lille Institute for Cancer Research), near the University Hospital.

Although OCR has largely expanded its activities to clinical research for veterinary health in various therapeutic areas, the company remains aligned with its values of “One Health”.

The installation of OCR within the IRCL is a logical continuation of OCR’s commitment and investments in cancer research projects within various academic-private consortia, including the OncoLille consortium and the joint PRISM-OCR research laboratory.

In a daily dynamic, this rapprochement perpetuates the fruitful exchanges between the different partners of human and veterinary medicine, and consolidates the conviction at the origin of which the OCR company was born.

OCR at the annual meeting of the European Society of Veterinary Oncology (ESVONC)


Between 25-27,of May OCR, represented by our Head of R&D Agata Rybicka, had participated in annual congress of European Society of Veterinary Oncology (ESVONC) in Alicante, Spain.

Morning sessions included discussions on the link between nutrition and cancer, the application of liquid biopsy in veterinary clinics and selected surgical procedures, while the afternoons were devoted to general presentations and abstract presentations by residents. It was also an opportunity for OCR to meet investigators participating in our clinical studies across Europe (Dr Jagielski and Dr Hildebrand pictured).

The OCR team is gradually expanding, including outside France. For the past few months, we have been working with our new local clinical research associate in Poland, Dr Karolina Ziomek.

Karolina completed her studies of veterinary medicine in Poland and her course in clinical trial monitoring and coordination.

She loves old, overweight Labradors, which she constantly adopts to help them lose weight. She currently owns Beza, Ora, Lena and a cat named Plamka.

MEET WITH OCR

PRESS RELEASES

  • LILLE, 17TH JANUARY 2019

    OCR and ImaBiotech initiate a strategic partnership to provide in situ drug efficacy and target exposure services in Pets with naturally occuring tumors.

  • LILLE, 02ND NOVEMBER 2018

    OCR and Biofortis discuss the importance of the microbiome, especially in the field of oncology, in an interview with Dr Tierny and Dr Rybicka.

  • LILLE, 17TH SEPTEMBER 2018

    OCR together with ImmunXperts and Rarecells win k€520 funding in Eureka Eurostars program to initiate €1,3m “ICOM” platform for preclinical and clinical human cancer drug evaluation in pet dog’s model.

  • LILLE, 6TH SEPTEMBER 2016

    OCR the company revolutionising the selection of effective drug candidates for cancer, raises €1.25m from Newfund, NFA and the management team in order to accelerate its growth.

  • LILLE, 16TH JULY 2015

    OCR and Pierre Fabre’s Phase I Clinical Pharmacology Study published in prestigious Clinical Cancer Research journal.

  • LILLE, 02ND APRIL 2015

    OCR and Ecrins Therapeutics initiate €1.9m “Dog to Man” pioneering translational research programme to advance human and vet oncology treatment.

  • LILLE, 23RD MARCH 2015

    OCR and PRISM announce ground-breaking research collaboration to advance real-time diagnosis using mass spectrometry.

  • LILLE, 30TH JANUARY 2015

    OCR strengthens veterinary and R&D expertise to respond to the needs of the pharmaceutical industry.

Stay connected to OCR,
subscribe to our Newsletter !

Contact Us

WE WOULD BE DELIGHTED TO HEAR FROM YOU !

OCR FRANCE

Fanny LEPRETRE

contact@oncovet-clinical-research.com

Bâtiment IRCL – 2 Place de Verdun – CS30038

59041 LILLE Cedex